Cargando…

Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series

(1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on MS disease activity in a cohort of relapsing–...

Descripción completa

Detalles Bibliográficos
Autores principales: Allinovi, Marco, Bellinvia, Angelo, Pesce, Francesco, Milan Manani, Sabrina, Razzolini, Lorenzo, Brezzi, Brigida, Protopapa, Paolo, Mantero, Vittorio, Caroti, Leonardo, Cirami, Calogero Lino, Amato, Maria Pia, Del Vecchio, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533854/
https://www.ncbi.nlm.nih.gov/pubmed/34679405
http://dx.doi.org/10.3390/brainsci11101341
_version_ 1784587413905997824
author Allinovi, Marco
Bellinvia, Angelo
Pesce, Francesco
Milan Manani, Sabrina
Razzolini, Lorenzo
Brezzi, Brigida
Protopapa, Paolo
Mantero, Vittorio
Caroti, Leonardo
Cirami, Calogero Lino
Amato, Maria Pia
Del Vecchio, Lucia
author_facet Allinovi, Marco
Bellinvia, Angelo
Pesce, Francesco
Milan Manani, Sabrina
Razzolini, Lorenzo
Brezzi, Brigida
Protopapa, Paolo
Mantero, Vittorio
Caroti, Leonardo
Cirami, Calogero Lino
Amato, Maria Pia
Del Vecchio, Lucia
author_sort Allinovi, Marco
collection PubMed
description (1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on MS disease activity in a cohort of relapsing–remitting (RR) MS patients who discontinued IFN-β therapy due to IFN-β-related thrombotic microangiopathy (TMA) onset. (2) Methods: In this retrospective observational multicentric study, we searched for all patients with MS treated by eculizumab with a survey of several nephrological and neurological centers (over 45 centers). (3) Results: Nine patients were included. The mean follow-up time under eculizumab was 3.72 ± 2.58 years. There were no significant differences in disease activity (EDSS, relapses, new T2, and/or Gd-enhancing lesions at MRI) considering the two years before and after eculizumab therapy. No adverse events potentially related to eculizumab therapy were reported during follow-up. (4) Conclusions: In this preliminary study, we described a good safety profile for eculizumab therapy in MS. However, the available data are not sufficient to make firm conclusions about the possible efficacy of eculizumab as a disease-modifying therapy for MS patients.
format Online
Article
Text
id pubmed-8533854
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85338542021-10-23 Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series Allinovi, Marco Bellinvia, Angelo Pesce, Francesco Milan Manani, Sabrina Razzolini, Lorenzo Brezzi, Brigida Protopapa, Paolo Mantero, Vittorio Caroti, Leonardo Cirami, Calogero Lino Amato, Maria Pia Del Vecchio, Lucia Brain Sci Article (1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on MS disease activity in a cohort of relapsing–remitting (RR) MS patients who discontinued IFN-β therapy due to IFN-β-related thrombotic microangiopathy (TMA) onset. (2) Methods: In this retrospective observational multicentric study, we searched for all patients with MS treated by eculizumab with a survey of several nephrological and neurological centers (over 45 centers). (3) Results: Nine patients were included. The mean follow-up time under eculizumab was 3.72 ± 2.58 years. There were no significant differences in disease activity (EDSS, relapses, new T2, and/or Gd-enhancing lesions at MRI) considering the two years before and after eculizumab therapy. No adverse events potentially related to eculizumab therapy were reported during follow-up. (4) Conclusions: In this preliminary study, we described a good safety profile for eculizumab therapy in MS. However, the available data are not sufficient to make firm conclusions about the possible efficacy of eculizumab as a disease-modifying therapy for MS patients. MDPI 2021-10-11 /pmc/articles/PMC8533854/ /pubmed/34679405 http://dx.doi.org/10.3390/brainsci11101341 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Allinovi, Marco
Bellinvia, Angelo
Pesce, Francesco
Milan Manani, Sabrina
Razzolini, Lorenzo
Brezzi, Brigida
Protopapa, Paolo
Mantero, Vittorio
Caroti, Leonardo
Cirami, Calogero Lino
Amato, Maria Pia
Del Vecchio, Lucia
Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
title Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
title_full Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
title_fullStr Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
title_full_unstemmed Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
title_short Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
title_sort safety and efficacy of eculizumab therapy in multiple sclerosis: a case series
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533854/
https://www.ncbi.nlm.nih.gov/pubmed/34679405
http://dx.doi.org/10.3390/brainsci11101341
work_keys_str_mv AT allinovimarco safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT bellinviaangelo safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT pescefrancesco safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT milanmananisabrina safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT razzolinilorenzo safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT brezzibrigida safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT protopapapaolo safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT manterovittorio safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT carotileonardo safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT ciramicalogerolino safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT amatomariapia safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries
AT delvecchiolucia safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries